Acumen Pharmaceuticals, Inc. (ABOS): Price and Financial Metrics


Acumen Pharmaceuticals, Inc. (ABOS): $3.92

-0.06 (-1.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABOS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ABOS Stock Price Chart Interactive Chart >

Price chart for ABOS

ABOS Price/Volume Stats

Current price $3.92 52-week high $10.97
Prev. close $3.98 52-week low $3.02
Day low $3.83 Volume 53,900
Day high $4.05 Avg. volume 81,123
50-day MA $5.30 Dividend yield N/A
200-day MA $5.78 Market Cap 158.77M

Acumen Pharmaceuticals, Inc. (ABOS) Company Bio


Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.


ABOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ABOS Latest Social Stream


Loading social stream, please wait...

View Full ABOS Social Stream

Latest ABOS News From Around the Web

Below are the latest news stories about ACUMEN PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ABOS as an investment opportunity.

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 22, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Wednesday, March 29, 2023 at 12:30 p.m. ET. The live webcast may be accessed under the Investors tab on www.

Yahoo | March 22, 2023

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2022 financial results on Monday, March 27, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business

Yahoo | March 20, 2023

Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Needham Virtual Neuroscience Forum on Wednesday, March 15, 2023 at 10:00 a.m. ET. The live webcast may be accessed under the Investors tab o

Yahoo | March 8, 2023

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | February 15, 2023

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial of

Yahoo | February 13, 2023

Read More 'ABOS' Stories Here

ABOS Price Returns

1-mo -25.76%
3-mo -24.76%
6-mo -11.71%
1-year -23.74%
3-year N/A
5-year N/A
YTD -27.41%
2022 -20.12%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7571 seconds.